Global Bleeding Disorders Treatment
Market Report
2024
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Bleeding Disorders Treatment Market Report 2024.
According to cognitive market research-"Global Bleeding Disorders Treatment market size 2023 was XX Million. Bleeding Disorders Treatment Industry compound annual growth rate (CAGR) will be XX% from 2024 till 2031."
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Market Split by Type |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Bleeding Disorders Treatment industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Bleeding Disorders Treatment Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Introduction to Bleeding Disorders Treatment market
A bleeding disorder refers to medical problems when blood does not clot properly. Symptoms of bleeding problems include frequent nosebleeds, severe menstrual bleeding, extensive bruising, and prolonged bleeding after vaccinations or surgery. They may be acquired or congenital. Haemophilia A & B and Von Willebrand's disease are the most frequent bleeding disorders among individuals. Other deficits include vitamin K, factor II, V, VII, X, and XII.
The increased prevalence of haemophilia around the world increases the demand for haemophilia treatments. As awareness spreads and diagnostic capabilities improve, more instances are identified and treated. The World Federation of Haemophilia (WFH) believes that one in every 5,000 males is born with haemophilia A, while one in every 30,000 is born with haemophilia B. According to the CDC, haemophilia is a genetic bleeding illness that affects around one out of every 5,617 live male births. This shows that there are approximately 30,000 to 33,000 men in the United States with haemophilia. Improved awareness, screening, and diagnosis have resulted in earlier detection of haemophilia cases.
https://elearning.wfh.org/elearning-centres/hemophilia/
Haemophilia is frequently underdiagnosed or misdiagnosed, which can lead to an underestimate of its prevalence. Improved awareness and diagnostic tools have contributed to the identification of more instances. So, on April 17, 2023, the WFH celebrated World Haemophilia Day, which aims to raise awareness of haemophilia and other inherited bleeding disorders. "Access for All: Prevention of Bleeds as the Global Standard of Care" was the 2023 theme. In early 2023, the FDA approved Altuviiio (efanesoctocog alfa) as a long-term FVIII replacement medication for those with haemophilia A. Altuviiio can treat bleeding both proactively and on-demand. As a result, the increasing prevalence of haemophilia, spurred by improved diagnosis, awareness campaigns, and the establishment of specialised treatment facilities, contributes to the haemophilia treatment market trend.
https://wfh.org/article/everything-you-need-for-world-hemophilia-day-2023/
The bleeding disorder testing market insights can be attributed to the increasing prevalence of difficulties in emerging and developed areas. These include idiopathic thrombocytopenic purpura, haemophilia A and B, von Willebrand disease, and others. Disorders such as haemophilia A, haemophilia B, and von Willebrand disease are becoming more common in the population.Because of the genetic diversity in both developing and developed regions. Patient attention to blood concerns, together with private-area and government treatment operations, helps to propel the Bleeding problem therapy market forward. Nonetheless, market expansion may be hampered by a lack of testing in emerging regions and a failure to follow standards.
Healthcare organisations' increasing efforts and initiatives have resulted in increased awareness of the available testing and treatment market. The Bleeding Problem Treatment Market is driven by the increased prevalence of bleeding disorders among people and the availability of treatments or medicines to treat these illnesses.
Haemophilia treatment, especially factor replacement therapies, can be costly. The excessive costs of these medications may place a significant financial strain on healthcare systems, individuals, and their families. The annual expense of treating haemophilia exceeds USD 393,000 per patient. Gene therapies can cure haemophilia, however each dose costs up to USD 3.5 million. These treatments are not typically curative. Replacement therapy in India ranges from Rs. 1,95,000 to Rs. 5,52,500, depending on the severity of the ailment.
Additionally, factor VIII and IX concentrates are the foundation of haemophilia treatment, especially in severe cases. These clotting factor concentrations are derived from human plasma or produced using recombinant technology. These factor concentrates can be expensive, and persons with haemophilia often need recurring infusions throughout their lives. According to Value in Health, the average wholesale price (AWP) per international unit (IU) for Factor VIII (FVIII) concentrates ranges between USD 1.35 and USD 2.56, while the range for Factor IX (FIX) consolidates is USD 1.31 to USD 5.28. Furthermore, TIFAC, the US Pharmaceutical Manufacturers Association, estimates that recombinant DNA treatments will cost approximately USD 250 million over the next ten years. This puts a huge financial load on healthcare systems and insurance.
Patients with haemophilia can be cured using gene therapy that restores continuous endogenous expression of factor VIII or factor IX (FIX). Bleeding has been greatly decreased, with some studies indicating a 91.5% reduction. Continued research and advancements in gene editing technology may lead to more effective and long-term haemophilia treatments. Several clinical trials were conducted to assess the safety and efficacy of gene therapy for haemophilia. In these trials, functional copies of the faulty clotting factor gene are inserted into patients' cells, allowing clotting factor synthesis. Notable examples include trials for haemophilia A and B.
The approval of gene therapy for haemophilia represents a significant opportunity. The acceptance of these treatments by regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) opens the door to commercialization and widespread patient access. In 2023, the FDA authorised Roctavian (valoctocogene roxaparvovec), the first gene treatment for severe haemophilia A. This one-time injection uses a vector to deliver a functional gene that substitutes the patient's defective one. The ultimate result is increased clotting factor activity, which prevents bleeding. Furthermore, successful gene therapies may alter the haemophilia therapy landscape by providing long-term or curative options. While the early costs of gene therapy may be substantial, the long-term economic impact could be huge.
The COVID-19 epidemic impacted the bleeding disorder treatment market. The COVID-19 pandemic had a significant impact on clinical trials for blood illnesses. In addition, hospitals cancelled haemophilia replacement treatments. Additionally, the travel ban and lockdown had an impact on the supply chain for bleeding disorders products.
COVID-19 is a potentially fatal infection that can cause a variety of symptoms, from asymptomatic to severe pneumonia and systemic complications. Hypertension, diabetes, cardiovascular disease, and immunosuppression are all considered risk factors. Haemophilia sufferers should not stop taking their treatment based on existing evidence. As COVID-19 proceeds, coagulation pathways become activated as part of the host's inflammatory response, resulting in increased D-dimers, which suggest clot formation and disintegration. More severe COVID-19 cases may result in overt disseminated intravascular coagulation (DIC), which is associated with a high mortality. All patients who develop signs or symptoms of DIC should be closely monitored for bleeding and thrombosis. Anticoagulants are advised as part of therapy plans for patients with high D-dimers and severe infection. Patients with haemophilia should continue prophylaxis with factor replacement therapy and be evaluated for further clotting factor replacement therapy. Patients enrolled in gene therapy clinical trials should consult with study sponsors and medical monitors for guidance.
The bleeding disorders treatment industry is driven by a large consumer base, improved awareness of potential therapies, and favourable compensation policies. Brand patents will expire, allowing generic companies to enter the bleeding disorder therapeutics market. Government initiatives and awareness programmes are projected to boost the bleeding disorders treatment market in the future years.
We have various report editions of Bleeding Disorders Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The global haemophilia therapy market is very active, with major players investing heavily in research and development to provide new medicines. Aside from that, companies have used growth tactics such as partnerships, mergers and acquisitions, new product launches and approvals, collaborations, and so on to obtain a competitive advantage in the worldwide haemophilia therapy market.
Top Companies Market Share in Bleeding Disorders Treatment Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Global Bleeding Disorders Treatment Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Bleeding Disorders Treatment Industry growth. Bleeding Disorders Treatment market has been segmented with the help of its Type, , and others. Bleeding Disorders Treatment market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
In 2023, Haemophilia A had the biggest haemophilia market share (XX%). It is a hereditary condition that results in a deficiency of blood clotting factor VIII. The high prevalence of haemophilia A in developed nations, as well as supportive government activities to introduce products in important markets such as the United States, Europe, and Japan, contribute to this dominance. According to WFH's 2020 survey, countries such as the United States, India, and Brazil lead with 10,000 type A cases.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Bleeding Disorders Treatment Industry. Request a Free Sample PDF!
In 2023, Haemophilia A had the biggest haemophilia market share (XX%). It is a hereditary condition that results in a deficiency of blood clotting factor VIII. The high prevalence of haemophilia A in developed nations, as well as supportive government activities to introduce products in important markets such as the United States, Europe, and Japan, contribute to this dominance. According to WFH's 2020 survey, countries such as the United States, India, and Brazil lead with 10,000 type A cases.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Bleeding Disorders Treatment market report 2024 Edition by contacting our team.
North America is the largest worldwide haemophilia treatment market shareholder, and it is expected to grow at a CAGR of XX% during the forecast period. It is expected to do the same over the projection period, owing to a growth in haemophilia cases, increased knowledge of technologically advanced products, and favourable regional government policies. Furthermore, a study published in Frontiers in Immunology in April 2021 discovered that in the United States, people with hereditary disorders such as haemophilia B benefited from Adeno-associated virus (AAV)-mediated gene transfer in order to achieve long-term therapeutic transgene expression. These discoveries improve gene therapy for haemophilia, hastening market growth.
Asia-Pacific is expected to grow at a CAGR of xx% over the forecast period due to a rise in the number of people with haemophilia. Furthermore, increased healthcare spending creates a profitable opportunity for market expansion. In mainland China, the overall prevalence of haemophilia is 3.6 per 100,000 people, with men accounting for 5.5 per 100,000. Over 65,000 persons in China are believed to have haemophilia. Thus, the haemophilia therapy market in China is likely to grow over the forecast period.
The current report Scope analyzes Bleeding Disorders Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
Senior Research Analyst at Cognitive Market Research
• Worked on several market, industry & business research projects, on various models such as Syndicated, Custom, Subscriptions and Consults
• Proficient in secondary research and familiar with all paid research databases
• Proficient in primary research and handling client queries through mails and calls
• Expertise in statistical techniques used in data forecasting, possess strong grip on all aspects of market engineering & data analysis
• Expertise in checking feasibility of projects based on Request for Proposal (RFPs) of clients
• Acquainted with entire process of report writing- Title Analysis, TOC Building, Search Engine Optimization, TOC Freezing, Writing Reports, Market Engineering, Scheduling Primaries, Directory of Key Industry Participants (DKIP), Drafting “Press Articles/Summary/Report Description/Analyst Briefing” used for making marketing collaterals
• Gained team-work skills in coordinating with the sales teams for business development and meeting needs of a variety of clients hand-in-hand with promoting sales.
I am a dynamic and results-driven research analyst with a passion for transforming raw data into actionable insights. Armed with a solid foundation in market research and data analysis, I thrive on the challenge of uncovering patterns, trends, and opportunities that drive strategic decision-making. My analytical mindset, coupled with effective communication skills, allows me to bridge the gap between data analysis and practical business applications.
I served as a key player in market research and competitive analysis. I have a proven track record of synthesizing disparate data sources, employing statistical models, and delivering comprehensive insights. Collaborating across departments, I played a pivotal role in shaping evidence-based strategies that fueled the success of key business initiatives. I am committed to ongoing professional development, participating in industry conferences, workshops, and pursuing additional certifications to stay at the forefront of research methodologies.
The bleeding disorders treatment market is expanding due to an increase in the number of patients diagnosed with bleeding disorders, increased research and development activities and investments by key players, increased awareness about bleeding disorders, particularly haemophilia, and positive government initiatives in developed countries to establish a large network of diagnosis and treatment centres, which are all contributing to market growth. However, the lack of access to adequate treatment due to high prescription costs and a shortage of competent health providers stifles market growth.
Table of Content differs accordign to the user License selction. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section's Or chapter's from the report. Specific section's of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Type | Hemophilia A, Hemophilia B, Von Willebrand Disease, Others |
List of Competitors | Takeda, Bayer, Biogen, CSL Behring, Novo Nordisk, Pfizer, Grifols |
This chapter will help you gain GLOBAL Market Analysis of Bleeding Disorders Treatment. Further deep in this chapter, you will be able to review Global Bleeding Disorders Treatment Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Chapter 2 North America Market Analysis
Executive Summary North America Market (2019 vs 2024 vs 2031)
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Bleeding Disorders Treatment Market Trends North America Bleeding Disorders Treatment Technological Road Map North America Bleeding Disorders Treatment Market Drivers North America Bleeding Disorders Treatment Market Restraints North America Bleeding Disorders Treatment Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
Chapter 3 Europe Market Analysis
Chapter 4 Asia-Pacific Market Analysis
Chapter 5 South America Market Analysis
Chapter 6 Middle East and Africa Market Analysis
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Bleeding Disorders Treatment market
Chapter 12 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Hemophilia A have a significant impact on Bleeding Disorders Treatment market? |
What are the key factors affecting the Hemophilia A and Hemophilia B of Bleeding Disorders Treatment Market? |
What is the CAGR/Growth Rate of during the forecast period? |
By type, which segment accounted for largest share of the global Bleeding Disorders Treatment Market? |
Which region is expected to dominate the global Bleeding Disorders Treatment Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Bleeding Disorders Treatment Market
Request Sample